Showing results (71-80 of 136) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumorsMalcolm Ranson, Mark R Middleton, John Bridgewater, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumorsDan M Patterson, Martin Zweifel, Mark R Middleton, et al.Science Translational Medicine|July 16, 2010
Quinone oxidoreductase-2-mediated prodrug cancer therapyMark R Middleton, Richard Knox, Emma Cattell, et al.BMC Cancer|July 24, 2021
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphomaStephen W Booth, Toby A Eyre, John Whittaker, et al.Oncotarget|October 27, 2015
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomideRoger Ramcharan, Tamara Aleksic, Wilfride Petnga Kamdoum, et al.Plos One|September 15, 2016
Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for DiagnosisPamela J Kaisaki, Anthony Cutts, Niko Popitsch, et al.British Journal of Cancer|February 14, 2018
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424Victoria K Woodcock, Sally Clive, Richard H Wilson, et al.Radiology|January 16, 2019
Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I TrialMichael D Gray, Paul C Lyon, Christophoros Mannaris, et al.The Lancet. Oncology|July 14, 2018
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trialPaul C Lyon, Michael D Gray, Christophoros Mannaris, et al.Nature Medicine|February 12, 2020
Peripheral CD8<sup>+</sup> T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanomaBenjamin P Fairfax, Chelsea A Taylor, Robert A Watson, et al.Pageof 14